| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
See Remarks | Chief Financial Officer
1 company
Sun Nelson is a See Remarks at AARD. Recent filings cover 3 purchases and 2 sales. Those positions are worth an estimated $184K at current prices.
Our model assigns Sun Nelson a below-average insider score of 31/100, based on 3 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -9.0%.
Sun Nelson's largest disclosed position is in AARD as See Remarks, worth about $184K. The recent filings there lean toward selling, a net 57,754 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | AARD Aardvark Therapeutics, Inc. | See Remarks | Sell10b5-1 | 76,754 | $5.15 | $394,957.45 | -68.4% | - | - | |
| Dec 11, 2025 | AARD Aardvark Therapeutics, Inc. | Chief Financial Officer | Buy | 3,000 | $14.40 | $43,200.00 | +2.8% | -66.7% | - | |
| Sep 9, 2025 | AARD Aardvark Therapeutics, Inc. | Chief Financial Officer | Buy | 6,000 | $8.07 | $48,439.80 | +6.0% | +74.7% | -37.8% | |
| Feb 14, 2025 | AARD Aardvark Therapeutics, Inc. | Chief Financial Officer | Buy | 10,000 | $16.00 | $160,000.00 | +11.2% | -31.7% | -9.0% |